Document Detail


Hepatocyte growth factor and left ventricular geometry in end-stage renal disease.
MedLine Citation:
PMID:  12511535     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hepatocyte growth factor is a pleiotropic cytokine with cardioprotective properties. Its serum concentration is markedly raised in end-stage renal disease. This study assessed the relation of hepatocyte growth factor (HGF) with left ventricular mass and geometry in end-stage renal disease. Serum HGF measurements and echocardiographic studies were performed in 185 patients receiving hemodialysis. Patients with serum HGF above the median (1.85 ng/mL) had more frequent cardiovascular complications. This cytokine was directly related to mean left ventricular wall thickness (r=0.23, P=0.002) and relative wall thickness (r=0.25, P=0.0001); a multivariate analysis showed that this relation was independent of other risk factors. Accordingly, the prevalence of left ventricular concentric geometry (either concentric left ventricular hypertrophy or remodeling) was much higher (n=49, 53%) among patients with HGF values above the median that in those with values < or =1.85 ng/mL (n=31, 34%). Furthermore, the risk for left ventricular concentric geometry was higher in patients with HGF values above the median (odds ratio, 2.57; 95% CI, 1.33 to 4.98; P=0.005), and multiple logistic regression analysis confirmed that this association was independent of other risk factors. In patients receiving hemodialysis, elevated serum HGF is associated with concentric left ventricular geometry. This is consistent with reports that link this cytokine to arterial remodeling and survival in patients with end-stage renal disease and suggests that it is part of a counterregulatory response aimed at attenuating cardiovascular damage in this high-risk population.
Authors:
Lorenzo S Malatino; Alessandro Cataliotti; Francesco A Benedetto; Benedetta Stancanelli; Ignazio Bellanuova; Paola Belluardo; Lorena Bonaiuto; Giovanni Tripepi; Francesca Mallamaci; Pietro Castellino; Carmine Zoccali
Related Documents :
7859895 - Abnormalities suggestive of cardiomyopathy in patients with type 2 diabetes of relative...
12018665 - Acute pulmonary edema in the emergency department: clinical and echocardiographic surve...
14618215 - Blood pressure, left ventricular mass and function in adult patients after successful r...
15297785 - Changes of the cardiac architectures and functions for chronic hemodialysis patients wi...
1283935 - An unusual cause of factitious mineralocorticoid excess.
17404195 - Patterns of ocular oscillation in oculopalatal tremor: imaging correlations.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Hypertension     Volume:  41     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2003 Jan 
Date Detail:
Created Date:  2003-01-03     Completed Date:  2003-01-10     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  88-92     Citation Subset:  IM    
Affiliation:
Clinica Medica L. Condorelli, Department of Internal Medicine, University of Catania, Ospedale Vittorio Emanuele, Italy. dmalatin@tin.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Female
Hepatocyte Growth Factor / blood*
Humans
Hypertrophy, Left Ventricular / etiology*,  ultrasonography
Kidney Failure, Chronic / blood,  complications*
Male
Middle Aged
Ventricular Remodeling*
Chemical
Reg. No./Substance:
67256-21-7/Hepatocyte Growth Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Myocardial fatty acid metabolism: independent predictor of left ventricular mass in hypertensive hea...
Next Document:  Endothelin-1 contributes to the Frank-Starling response in hypertrophic rat hearts.